Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical impl...

por Vernieri, Claudio, Corti, Francesca, Nichetti, Federico, Ligorio, Francesca, Manglaviti, Sara, Zattarin, Emma, Rea, Carmen G., Capri, Giuseppe, Bianchi, Giulia V., de Braud, Filippo
Publicado 2020

Characterizing Different Multidisciplinary Team Models Implemented Within One Comprehensive Cancer Center

por Alfieri, Sara, Brunelli, Cinzia, Borreani, Claudia, Capri, Giuseppe, Angi, Martina, Bianchi, Giulia V, Lo Dico, Silvia, Spada, Pierangelo, Fusetti, Viviana, Zecca, Ernesto, Caraceni, Augusto
Publicado 2023

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Tax...

por Ligorio, Francesca, Fucà, Giovanni, Zattarin, Emma, Lobefaro, Riccardo, Zambelli, Luca, Leporati, Rita, Rea, Carmen, Mariani, Gabriella, Bianchi, Giulia V., Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio
Publicado 2021

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin

por Zattarin, Emma, Nichetti, Federico, Ligorio, Francesca, Mazzeo, Laura, Lobefaro, Riccardo, Fucà, Giovanni, Peverelli, Giorgia, Vingiani, Andrea, Bianchi, Giulia V., Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio
Publicado 2022

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

por Ligorio, Francesca, Zambelli, Luca, Bottiglieri, Achille, Castagnoli, Lorenzo, Zattarin, Emma, Lobefaro, Riccardo, Ottini, Arianna, Vingiani, Andrea, Pupa, Serenella M., Bianchi, Giulia V., Capri, Giuseppe, Pruneri, Giancarlo, de Braud, Filippo, Vernieri, Claudio
Publicado 2021

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

por Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd
Publicado 2020

Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospec...

por Lobefaro, Riccardo, Zattarin, Emma, Nichetti, Federico, Prisciandaro, Michele, Ligorio, Francesca, Brambilla, Marta, Sepe, Pierangela, Corti, Francesca, Peverelli, Giorgia, Ottini, Arianna, Beninato, Teresa, Mazzeo, Laura, Rea, Carmen G., Mariani, Gabriella, de Braud, Filippo, Bianchi, Giulia V., Vernieri, Claudio, Capri, Giuseppe
Publicado 2020